Ebola Outbreak in the DRC Passes 9,300 Confirmed Cases. There Is No Approved Treatment or Vaccine for This Strain.
CDC reports 9,300 confirmed cases and 4,481 confirmed deaths from Bundibugyo virus as of Oct. 14, with no US cases. The approved Ebola antibodies and vaccine do not cover this species, so recognition and isolation matter most.
The Bundibugyo virus outbreak centered in the Democratic Republic of the Congo has reached 9,300 confirmed cases and 4,481 confirmed deaths as of Oct. 14, according to the Centers for Disease Control and Prevention (CDC). The agency calls it the second-largest Ebola outbreak on record. No case linked to it has been reported in the United States.
For most practices the risk is one of recognition, not volume. But CDC's situation summary describes an outbreak that has outrun its predecessors, and a returning traveler with fever is a scenario any clinic or emergency department can face with little warning.
Where the outbreak stands
CDC counts 9,277 confirmed cases and 4,478 confirmed deaths in the DRC, with confirmed cases in seven provinces: Bas-Uele, Haut-Uele, Ituri, Nord-Kivu, Sud-Kivu, Sud-Ubangi and Tshopo. The DRC's health ministry excludes probable cases from its official figures, and suspected cases and deaths still under investigation are left out for now, so the true burden is likely higher.
Uganda has had 20 confirmed cases and one probable case, including cases in Kampala; its last confirmed patient was released from care on July 16, and CDC reports no active cases there. Kenya has reported two confirmed cases and one death. France had one confirmed case, released from care on July 4.
CDC says the outbreak passed 1,000 confirmed cases within 40 days of response activation; the 2018 DRC outbreak took about 235 days to reach that mark. In a Contagion Live report on the Oct. 6 data, CDC was described as saying the outbreak is "spreading substantially faster than previous Ebola outbreaks." The agency cites ongoing conflict, violence against health care workers, shortages of personal protective equipment and misinformation, and notes that health care workers are being infected while treating patients.
The practical risk in a US clinic is not volume. It is a febrile traveler who is screened late.
What CDC says clinicians should do
CDC's clinical guidance, last updated May 27, asks clinicians to consider Ebola in patients with consistent symptoms and recent travel to an area with an active outbreak. It also notes that most ill travelers returning from such areas have a more common infection, such as malaria, and says not to delay testing and care for those more likely conditions.
If Ebola is possible, isolate the patient in a single room immediately, with proper personal protective equipment and dedicated equipment, and contact the jurisdictional health department at once. Decisions about testing are made with public health officials and CDC. The agency's Viral Special Pathogens Branch offers consultation around the clock through the CDC Emergency Operations Center at 770-488-7100.
Treatment and vaccine limits
This is the point that differs from the outbreaks many clinicians remember. CDC states that the FDA-approved monoclonal antibodies, Inmazeb and Ebanga, and the Ervebo vaccine are approved only for disease caused by Ebola virus (Orthoebolavirus zairense). There are no FDA-licensed or authorized vaccines or therapeutics for Bundibugyo virus. Candidate treatments remain under investigation and are backed primarily by preclinical evidence, so care is supportive: volume repletion, vasopressors if needed, oxygen, pain control, nutritional support and treatment of secondary infections.
Travel rules and US risk
Under CDC's current rules, travelers who were in the DRC within 21 days of their flight cannot board commercial flights to the US, and US citizens and nationals who were there are told to stay outside the DRC for 21 days before entering. Citizens and nationals who were in Uganda or South Sudan, but not the DRC, must enter through designated airports for enhanced screening. CDC rates the likelihood of spread to the US as very low and the risk to the American public as low.
What practices should do now
Confirm that front-desk and triage staff ask about travel in the past 21 days when a patient reports fever, and that the question names Central and East Africa. Decide in advance which room you would use for isolation and who calls the health department. Keep the CDC consultation number with your triage protocol. Flu season is also starting early, which will put more febrile patients in your waiting room and make a consistent travel question more important, not less.
Reported, fact-checked and edited by The Script Pad's editorial staff.
This article is for professional education and does not replace clinical judgment. Treatment decisions should be based on the individual patient and current guidelines.
